Thank you for your interest in this webinar. By viewing this presentation, you will experience a presentation from a top-ranked scientist on the use of stable isotopes in clinical mass spectrometry.
The Opportunities and Challenges of Metabolomics Biomarkers Discovery and Development in Clinical Diagnostics
Huafen Liu | Founder and President
Calibra Diagnostics | China
Abstract: Metabolomics is a series of systematic analysis of endogenous metabolites in biological samples. To improve the clinical course of diseases, prevention and precision, clinical diagnostics are desired. In order to achieve this, metabolomics offers new opportunities for biomarker discovery in complex diseases and may provide pathological understanding of diseases beyond traditional clinical diagnostics. It is critical to have reliable and consistent data for product development. This presentation will highlight the opportunities and challenges of Metabolomics biomarkers discovery and development in clinical diagnostics.
During this webinar, you will learn about:
A transcript of this presentation is available in English here.
Huafen Liu | Founder and President of Calibra Diagnostics, China
Huafen Liu is the founder and President of Calibra Diagnostics, a leading omics and clinical diagnostic total solution provider in China. Calibra focuses on the application, reagent and product development of a variety of mass spectrometry applications in clinical diagnostics and life sciences.
Huafen worked at Pfizer, Roche and SCIEX Danaher Cooperation in US for more than 20 years. She was the Global Director of SCIEX Labs before she founded Calibra in 2017. She has more than 100 publications and received the AOAC international “Technical and Scientific Excellent of the year 2015-2016 Award”. Her publication in Cell “Proteomic and Metabolomic Characterization of COVID-19 Patient Sera” has been cited more than 650 times and commented on NIH Director’s blog by Dr. Francis Collins as “First Molecular Profiles of Severe COVID-19 Infections”.